Posted on 5/10/2018
LimFlow, developer of minimally-invasive technology for the treatment of end-stage critical limb ischaemia (CLI), has announced the expansion of the company’s senior management team. Sophie Humbert has been appointed to the role of chief operating officer (COO) and Thomas Engels, III, has assumed the role of vice president of clinical affairs. The Paris, France-based company also announced the opening of its first US office in Silicon Valley, USA.
Prior to joining LimFlow, Humbert was the COO of Arterial Remodeling Technologies (Terumo). Previously, Humbert was CEO at CermaVein, where she led the company through CE marking and to commercialisation in several markets. Humbert holds a PhD in Pharmaceutical Sciences from the University of Geneva, Geneva, Switzeland, a Master’s degree in Management from EM Lyon, Lyon,...